On diabetic foot, wound healing, amputation prevention, and the merger of consumer tech with medical devices
As the global burden of diabetes continues to climb, so too does the impact of its most feared complications—including diabetic foot ulcers (DFUs), infections, and amputations. While tight glycemic control has long been a cornerstone of diabetic foot prevention, emerging therapies are now offering benefits that go beyond glucose reduction. In our newly accepted paper... Continue Reading →
A new nationwide study out of Taiwan adds fresh weight to the growing list of potential benefits offered by GLP-1 receptor agonists (GLP-1RAs)—a class of medications already known for their glycemic control, cardiovascular protection, and weight loss benefits. This time, the focus is on something more insidious: infections that land people in the hospital. In... Continue Reading →
Screenshot In a recent New York Times article, Gina Kolata explores a striking trend in modern medicine: physicians, particularly in cardiology and endocrinology, are increasingly turning to GLP-1 receptor agonists like Ozempic, Wegovy, and Zepbound—not just for their patients, but for themselves. The piece highlights how these medications, initially designed to manage diabetes, are now being embraced by medical professionals... Continue Reading →
Introduction The battle against diabetic foot ulcers (DFUs) remains one of the most challenging aspects of diabetes care. With recent advances in diabetes medications, specifically GLP-1 receptor agonists (GLP-1 RAs), there is growing interest in how these drugs might support wound healing and improve DFU outcomes. Traditionally prescribed for glycemic control, GLP-1 RAs are showing... Continue Reading →
